Overview
  • Contains sulfadiazine/trimethoprim 400 mg/ml (333 mg sulfadiazine and 67 mg trimethoprim)
  • Proven effective in horses for the treatment of lower respiratory tract infections caused by susceptible strains of Streptococcus equi subsp. zooepidemicus
  • Safety was demonstrated in a controlled study in horses at 1x, 3x and 5x the recommended dose for 30 days
  • Easy-to-use liquid formulation
  • Significantly higher bioavailability on a mg-to-mg basis compared to an existing approved paste product, based on a pharmokinetic crossover study
  • Low incidence of side effects in controlled safety studies